What they were paid
Revance Therapeutics Director Compensation Table · the one fiscal year held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2023 | $80,000 | $118,778 | $118,755 | $0 | $317,533 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Revance Therapeutics, Inc. DEF 14A filed March 21, 2024, accession 0001479290-24-000071, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2023Revance Therapeutics pays directors a $50,000 cash retainer and $225,000 in 50% RSAs / 50% Options.
Committees
FY2023 · as the proxy prints themCompensation (Chair) · Brand Strategy
The rest of the Revance Therapeutics board
FY2023 · as the company reported each| Director | Role | FY2023 total |
|---|---|---|
| Angus C. Russell | Chair of the Board | $346,033 |
| Carey O'Connor Kolaja | Independent Director | $304,183 |
| Christian W. Nolet | Independent Director | — |
| Julian S. Gangolli | Independent Director | $305,033 |
| Mark J. Foley | Director | $0 |
| Olivia C. Ware | Independent Director | $295,033 |
| Vlad Coric, M.D | Independent Director | $421,490 |
The full Revance Therapeutics compensation record
free company briefThis page is one director within Revance Therapeutics's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat